Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

BACKGROUND: Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) remains the only approved medication for acute ischemic stroke, but incurs significant bleeding risks. Therefore, approaches to combine lower doses of thrombolytic therapy with other effective drugs aim at improvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimann, Andreas, Li, Zhongmin, Goebel, Silvia, Fassbender, Julia, Holthoff, Hans-Peter, Gawaz, Meinrad, Münch, Götz, Ungerer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wichtig 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072291/
https://www.ncbi.nlm.nih.gov/pubmed/27924212
http://dx.doi.org/10.5301/heartint.5000229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072291/
https://www.ncbi.nlm.nih.gov/pubmed/27924212
http://dx.doi.org/10.5301/heartint.5000229

Ejemplares similares